MiR-23a-mediated inhibition of topoisomerase 1 expression potentiates cell response to etoposide in human hepatocellular carcinoma

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Wang, Ning ^a   Zhu, Meifen ^a   Tsao, Sai Wah ^b   Man, Kwan ^b   Zhang, Zhangjin ^a   Feng, Yibin ^a  

^a THE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

DNA damage; Etoposide; Hepatocellular carcinoma; miR 23a; Topoisomerase 1

Indexed keywords

DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; MESSENGER RNA; MICRORNA; MICRORNA 23A; PROTEIN P53; TOPOISOMERASE 2A; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; DRUG MECHANISM; EMBRYO; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; UPREGULATION;

3' UNTRANSLATED REGIONS; ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BASE SEQUENCE; BINDING SITES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; RNA INTERFERENCE; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84885000772     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-119     Document Type: Article

References (34)

1. Pillai RS, Bhattacharyya SN, Filipowicz W. Repression of protein synthesis by miRNAs: how many mechanisms?. Trends Cell Biol 2007, 17:118-126. 10.1016/j.tcb.2006.12.007, 17197185.
2. Zhong X, Coukos G, Zhang L. miRNAs in human cancer. Methods Mol Biol 2012, 822:295-306. 10.1007/978-1-61779-427-8_21, 22144208.
3. Zhu LH, Liu T, Tang H, Tian RQ, Su C, Liu M, Li X. MicroRNA-23a promotes the growth of gastric adenocarcinoma cell line MGC803 and downregulates interleukin-6 receptor. FEBS J 2010, 277:3726-3734. 10.1111/j.1742-4658.2010.07773.x, 20698883.
4. Nair VS, Maeda LS, Ioannidis JP. Clinical outcome prediction by microRNAs in human cancer: a systematic review. J Natl Cancer Inst 2012, 104:528-540. 10.1093/jnci/djs027, 3317879, 22395642.
5. Gu Z, Zhang C, Wang J. Gene regulation is governed by a core network in hepatocellular carcinoma. BMC Syst Biol 2012, 6:32. 10.1186/1752-0509-6-32, 3403900, 22548756.
6. Xia L, Zhang D, Du R, Pan Y, Zhao L, Sun S, Hong L, Liu J, Fan D. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 2008, 123:372-379. 10.1002/ijc.23501, 18449891.
7. Hummel R, Hussey DJ, Haier J. MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer 2010, 46:298-311. 10.1016/j.ejca.2009.10.027, 19948396.
8. Burgess DJ, Doles J, Zender L, Xue W, Ma B, McCombie WR, Hannon GJ, Lowe SW, Hemann MT. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci USA 2008, 105:9053-9058. 10.1073/pnas.0803513105, 2435590, 18574145.
9. Hande KR. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 1998, 34:1514-1521. 10.1016/S0959-8049(98)00228-7, 9893622.
10. Moitra K, Im K, Limpert K, Borsa A, Sawitzke J, Robey R, Yuhki N, Savan R, Huang da W, Lempicki RA, Bates S, Dean M. Differential gene and MicroRNA expression between etoposide resistant and etoposide sensitive MCF7 breast cancer cell lines. PLoS One 2012, 7:e45268. 10.1371/journal.pone.0045268, 3445463, 23028896.
11. Lee TK, Man K, Ho JW, Wang XH, Poon RT, Sun CK, Ng KT, Ng IO, Xu R, Fan ST. Significance of the Rac signaling pathway in HCC cell motility: implications for a new therapeutic target. Carcinogenesis 2005, 26:681-687.
12. Wang N, Feng Y, Zhu M, Tsang CM, Man K, Tong Y, Tsao SW. Berberine induces autophagic cell death and mitochondrial apoptosis in liver cancer cells: the cellular mechanism. J Cell Biochem 2010, 111:1426-1436. 10.1002/jcb.22869, 20830746.
13. Srikantan S, Abdelmohsen K, Lee EK, Tominaga K, Subaran SS, Kuwano Y, Kulshrestha R, Panchakshari R, Kim HH, Yang X, Martindale JL, Marasa BS, Kim MM, Wersto RP, Indig FE, Chowdhury D, Gorospe M. Translational control of TOP2A influences doxorubicin efficacy. Mol Cell Biol 2011, 31:3790-3801. 10.1128/MCB.05639-11, 3165726, 21768308.
14. Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, Qin LX, Man K, Lo CM, Lee J, Ng IO, Fan J, Tang ZY, Sun HC, Wang. XW MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009, 361:1437-1447. 10.1056/NEJMoa0901282, 2786938, 19812400.
15. Wang B, Hsu SH, Frankel W, Ghoshal K, Jacob ST. Stat3-mediated activation of microRNA-23a suppresses gluconeogenesis in hepatocellular carcinoma by down-regulating glucose-6-phosphatase and peroxisome proliferator-activated receptor gamma, coactivator 1 alpha. Hepatology 2012, 56:186-197. 10.1002/hep.25632, 3355233, 22318941.
16. Gudkov AV, Zelnick CR, Kazarov AR, Thimmapaya R, Suttle DP, Beck WT, Roninson IB. Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA. Proc Natl Acad Sci USA 1993, 90:3231-3235. 10.1073/pnas.90.8.3231, 46273, 8386368.
17. Olsen PH, Ambros V. The lin-4 regulatory RNA controls developmental timing in Caenorhabditis elegans by blocking LIN-14 protein synthesis after the initiation of translation. Dev Biol 1999, 216:671-680. 10.1006/dbio.1999.9523, 10642801.
18. Canman CE, Wolff AC, Chen CY, Fornace AJ, Kastan MB. The p53-dependent G1 cell cycle checkpoint pathway and ataxia-telangiectasia. Cancer Res 1994, 54:5054-5058.
19. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K. Modulation of microRNA processing by p53. Nature 2009, 460:529-533. 10.1038/nature08199, 19626115.
20. Han C, Wan G, Langley RR, Zhang X, Lu X. Crosstalk between the DNA damage response pathway and microRNAs. Cell Mol Life Sci 2012, 69:2895-2906. 10.1007/s00018-012-0959-8, 22430204.
21. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, Arking DE, Beer MA, Maitra A, Mendell JT. Trans- activation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007, 26:745-752. 10.1016/j.molcel.2007.05.010, 1939978, 17540599.
22. Yan HL, Xue G, Mei Q, Wang YZ, Ding FX, Liu MF, Lu MH, Tang Y, Yu HY, Sun SH. Repression of the miR-17-92 cluster by p53 has an important function in hypoxia-induced apoptosis. EMBO J 2009, 28:2719-2732. 10.1038/emboj.2009.214, 2750010, 19696742.
23. Jahid S, Sun J, Edwards RA, Dizon D, Panarelli NC, Milsom JW, Sikandar SS, Gümüs ZH, Lipkin SM. miR-23a promotes the transition from indolent to invasive colorectal cancer. Cancer Discov 2012, 2:489-491. 10.1158/2159-8290.CD-12-0177, 3375870, 22684455.
24. Pommier Y, Barcelo JM, Rao VA, Sordet O, Jobson AG, Thibaut L, Miao ZH, Seiler JA, Zhang H, Marchand C, Agama K, Nitiss JL, Redon C. Repair of topoisomerase I-mediated DNA damage. Prog Nucleic Acid Res Mol Biol 2006, 81:179-229. 2576451, 16891172.
25. Trigueros S, Roca J. Failure to relax negative supercoiling of DNA is a primary cause of mitotic hyper-recombination in topoisomerase-deficient yeast cells. J Biol Chem 2002, 277:37207-37211. 10.1074/jbc.M206663200, 12151411.
26. Uemura T, Yanagida M. Isolation of type I and II DNA topoisomerase mutants from fission yeast: single and double mutants show different phenotypes in cell growth and chromatin organization. EMBO J 1984, 3:1737-1744. 557590, 6090122.
27. Helmbach H, Kern MA, Rossmann E, Renz K, Kissel C, Gschwendt B, Schadendorf D. Drug resistance towards etoposide and cisplatin in human melanoma cells is associated with drug-dependent apoptosis deficiency. J Invest Dermatol 2002, 118:923-932. 10.1046/j.1523-1747.2002.01786.x, 12060385.
28. Whitacre CM, Zborowska E, Willson JK, Berger NA. Detection of poly(ADP-ribose) polymerase cleavage in response to treatment with topoisomerase I inhibitors: a potential surrogate end point to assess treatment effectiveness. Clin Cancer Res 1999, 5:665-672.
29. Meley D, Spiller DG, White MR, McDowell H, Pizer B, Sée V. p53-mediated delayed NF-κB activity enhances etoposide-induced cell death in medulloblastoma. Cell Death Dis 2010, 1:e41. 10.1038/cddis.2010.16, 3032310, 21364648.
30. Liu N, Wang J, Wang J, Wang R, Liu Z, Yu Y, Lu H. ING5 Is a Tip60 cofactor that acetylates p53 in response to DNA damage. Cancer Res 2013, 73:3749-3760. 10.1158/0008-5472.CAN-12-3684, 23576563.
31. Kim JH, Chae M, Kim WK, Kim YJ, Kang HS, Kim HS, Yoon S. Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein. Br J Pharmacol 2011, 162:773-784. 10.1111/j.1476-5381.2010.01089.x, 3041264, 20973777.
32. Li Y, Dai C, Li J, Wang W, Song G. Bid-overexpression regulates proliferation and phosphorylation of Akt and MAPKs in response to etoposide-induced DNA damage in hepatocellular carcinoma cells. Onco Targets Ther 2012, 5:279-286. 3477928, 23093908.
33. Wang Z, Wei W, Sarkar FH. miR-23a, a critical regulator of " migR" ation and metastasis in colorectal cancer. Cancer Discov 2012, 2:489-491. 10.1158/2159-8290.CD-12-0177, 3375870, 22684455.
34. Owens C, Laurence V, Benboubker L, Defachelles AS, Cupissol D, Rubie H, Brisse H, Rey A, Ollivier L, Couanet D, Baunin C, Aït-Oukhatar CM, Oberlin O. Phase II study of cisplatin and oral VP16 in patients with refractory or relapsed Ewing sarcoma. Cancer Chemother Pharmacol 2013, 71:399-404. 10.1007/s00280-012-2015-7, 23161409.